- Home
- ALLO vs BALY Comparison
ALLO vs BALY Comparison
Compare ALLO & BALY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | BALY |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | 11700 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 731.8M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ALLO | BALY |
|---|---|---|
| Price | $1.96 | $14.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 5 |
| Target Price | $8.35 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 7.8M | 46.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | 8.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,436,189,000.00 |
| Revenue This Year | N/A | $21.50 |
| Revenue Next Year | $142,416.42 | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $8.79 |
| 52 Week High | $4.46 | $20.74 |
Technical Indicators
Market Signals| Indicator | ALLO | BALY |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 55.00 |
| Support Level | $1.56 | $12.59 |
| Resistance Level | $1.92 | $14.77 |
| Average True Range (ATR) | 0.12 | 0.80 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 40.82 | 78.67 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About BALY Bally's Corporation
Ballys Corp is a gaming, hospitality, entertainment, and technology company operating across casino, interactive, and lottery markets. It provides physical and interactive gaming experiences, including casino gaming, iGaming, sportsbook, online bingo, free-to-play games, and technology-driven lottery solutions. The company's segments include Casinos & Resorts, which generates maximum revenue and operates casino and resort properties, a horse racetrack, and a golf course; Bally's Intralot B2B, which provides lottery and technology services; Bally's Intralot B2C, which includes interactive gaming and lottery operations, including a UK casino; and North America Interactive, which includes sports betting and iGaming operations in the United States and Canada.